Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Down 34.6% in August

Key Points

• Chugai Pharmaceutical experienced a significant 34.6% drop in short interest in August, with a current total of 15,900 shares short as of August 31st.
• The company reported $2.01 billion in revenue for the quarter with an earnings per share (EPS) of $0.20.
• Chugai Pharmaceutical stock opened at $22.61 and has a market capitalization of $74.41 billion, with a 12-month high of $31.26 and a low of $19.50.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 15,900 shares, a decrease of 34.6% from the August 15th total of 24,300 shares. Based on an average daily volume of 474,800 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company's stock are sold short. Currently, 0.0% of the company's stock are sold short. Based on an average daily volume of 474,800 shares, the short-interest ratio is presently 0.0 days.

Chugai Pharmaceutical Stock Performance

Shares of OTCMKTS CHGCY traded up $0.04 during trading on Friday, hitting $23.05. 8,308 shares of the company traded hands, compared to its average volume of 203,035. The business's fifty day moving average is $22.77 and its 200 day moving average is $24.45. Chugai Pharmaceutical has a fifty-two week low of $19.50 and a fifty-two week high of $31.26. The firm has a market capitalization of $75.87 billion, a price-to-earnings ratio of 29.18 and a beta of 0.65.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last posted its earnings results on Thursday, July 24th. The company reported $0.20 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 33.08% and a return on equity of 20.80%. The company had revenue of $2.01 billion for the quarter. On average, analysts predict that Chugai Pharmaceutical will post 0.74 EPS for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.